OP0029 Baricitinib, An Oral Janus Kinase (JAK)1/JAK2 Inhibitor, in Patients with Active Rheumatoid Arthritis (RA) and an Inadequate Response to TNF Inhibitors: Results of the Phase 3 RA-Beacon Study - Concepedia

Concepedia

Publication | Closed Access

OP0029 Baricitinib, An Oral Janus Kinase (JAK)1/JAK2 Inhibitor, in Patients with Active Rheumatoid Arthritis (RA) and an Inadequate Response to TNF Inhibitors: Results of the Phase 3 RA-Beacon Study

26

Citations

0

References

2015

Year

M. C. Genovese, Joel M. Kremer, Omid Zamani, Charles Ludivico, Marek Krogulec, Lechun Xie, Scott D. Beattie, A E Koch, T. Cardillo, Terence Rooney,

Annals of the Rheumatic Diseases

No additional data available for this publication yet. Check back later!